Janone (ALTS) Competitors $2.10 -0.01 (-0.47%) (As of 12:09 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsShort InterestTrends ALTS vs. COYA, GBIO, VXRT, NVCT, BNTC, IPSC, CLLS, DERM, KPTI, and PLXShould you be buying Janone stock or one of its competitors? The main competitors of Janone include Coya Therapeutics (COYA), Generation Bio (GBIO), Vaxart (VXRT), Nuvectis Pharma (NVCT), Benitec Biopharma (BNTC), Century Therapeutics (IPSC), Cellectis (CLLS), Journey Medical (DERM), Karyopharm Therapeutics (KPTI), and Protalix BioTherapeutics (PLX). These companies are all part of the "pharmaceutical products" industry. Janone vs. Coya Therapeutics Generation Bio Vaxart Nuvectis Pharma Benitec Biopharma Century Therapeutics Cellectis Journey Medical Karyopharm Therapeutics Protalix BioTherapeutics Janone (NASDAQ:ALTS) and Coya Therapeutics (NASDAQ:COYA) are both small-cap finance companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk. Does the MarketBeat Community believe in ALTS or COYA? Coya Therapeutics received 14 more outperform votes than Janone when rated by MarketBeat users. CompanyUnderperformOutperformJanoneN/AN/ACoya TherapeuticsOutperform Votes1493.33% Underperform Votes16.67% Do analysts recommend ALTS or COYA? Coya Therapeutics has a consensus price target of $16.67, indicating a potential upside of 171.00%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Coya Therapeutics is more favorable than Janone.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janone 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, ALTS or COYA? Janone has a beta of 2.15, suggesting that its stock price is 115% more volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Which has stronger valuation and earnings, ALTS or COYA? Janone has higher earnings, but lower revenue than Coya Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanone$2.17M13.62-$7.81MN/AN/ACoya Therapeutics$6M17.13-$7.99M-$0.65-9.46 Is ALTS or COYA more profitable? Coya Therapeutics' return on equity of -31.63% beat Janone's return on equity.Company Net Margins Return on Equity Return on Assets JanoneN/A -2,940.01% -39.81% Coya Therapeutics N/A -31.63%-27.76% Does the media prefer ALTS or COYA? In the previous week, Coya Therapeutics had 10 more articles in the media than Janone. MarketBeat recorded 13 mentions for Coya Therapeutics and 3 mentions for Janone. Janone's average media sentiment score of 0.96 beat Coya Therapeutics' score of 0.93 indicating that Janone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janone 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coya Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in ALTS or COYA? 6.3% of Janone shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 4.9% of Janone shares are held by insiders. Comparatively, 12.0% of Coya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryCoya Therapeutics beats Janone on 11 of the 14 factors compared between the two stocks. Ad Behind the Markets❗ RSVP please!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Just click here and secure your spot! Get Janone News Delivered to You Automatically Sign up to receive the latest news and ratings for ALTS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALTS vs. The Competition Export to ExcelMetricJanonePharmaceutical IndustryFinance SectorNASDAQ ExchangeMarket Cap$29.55M$6.32B$10.25B$8.73BDividend YieldN/A8.11%10.48%4.07%P/E RatioN/A9.8647.4817.15Price / Sales13.62365.863,318.0490.61Price / CashN/A50.7530.1835.18Price / Book8.089.803.675.89Net Income-$7.81M$150.49M$983.43M$223.24M7 Day Performance-10.64%-5.05%-0.74%0.60%1 Month Performance-16.00%-4.77%1.91%5.06%1 Year PerformanceN/A30.44%24.71%26.70% Janone Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTSJanone1.4378 of 5 stars$2.10-0.5%N/AN/A$29.55M$2.17M0.00170COYACoya Therapeutics3.0695 of 5 stars$6.81-5.9%N/A+18.1%$113.80M$6M-10.486Short Interest ↑GBIOGeneration Bio3.5199 of 5 stars$1.68-8.2%N/A+35.7%$112.21M$5.90M-0.77150Positive NewsVXRTVaxart2.2136 of 5 stars$0.63-11.3%N/A-27.4%$111.78M$15.65M-1.37109Gap UpNVCTNuvectis Pharma3.0906 of 5 stars$5.73-46.3%N/A-39.6%$110.70MN/A-4.948Gap DownHigh Trading VolumeBNTCBenitec Biopharma2.3005 of 5 stars$10.40-0.4%N/A+211.4%$109.78M$80,000.000.0020IPSCCentury Therapeutics2.4008 of 5 stars$1.26-5.3%N/A-11.6%$107.14M$2.23M-0.68170Short Interest ↑High Trading VolumeCLLSCellectis3.5998 of 5 stars$1.91-3.5%N/A-36.2%$106.17M$29.07M-1.47290DERMJourney Medical3.2699 of 5 stars$5.08-0.8%N/AN/A$105.29M$77.68M-5.4090Short Interest ↓KPTIKaryopharm Therapeutics4.1378 of 5 stars$0.84-3.5%N/A+4.4%$104.93M$146.03M-0.73380Positive NewsPLXProtalix BioTherapeuticsN/A$1.41+13.7%N/A-0.4%$103.69M$65.49M-7.05200Gap DownHigh Trading Volume Related Companies and Tools Related Companies COYA Alternatives GBIO Alternatives VXRT Alternatives NVCT Alternatives BNTC Alternatives IPSC Alternatives CLLS Alternatives DERM Alternatives KPTI Alternatives PLX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALTS) was last updated on 11/18/2024 by MarketBeat.com Staff From Our Partners5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredFREE investing Class TOMORROW + 2 FREE BonusesOver the last 37 years on Wall Street, I've developed a unique investing strategy that allows me to find stock...Unstoppable Prosperity | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored🗓️ My First LIVE Event in 5 Years!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Behind the Markets | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janone Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janone With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
